ClinicalTrials.gg
CompletedNCT05296538MISSTUpdated Mar 6, 2024

The Mental Imagery for Suicidality in Students Trial (MISST)

An interventional study of Broad-Minded Affective Coping Intervention and Risk Assessment and Signposting in Suicide, Attempted and Suicidal Ideation, sponsored by Greater Manchester Mental Health NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Greater Manchester Mental Health NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In the UK, suicide is the leading cause of death in young people and have increased in recent years. Areas in the North of England appear particularly at risk. University students represent one vulnerable group. 42% of students contemplate suicide in any one-year period. Suicidal thinking is an important indicator of distress and clinical need, which predicts subsequent suicidal experiences and worse mental health. It is therefore an important target for clinical treatment and early intervention. However, evidenced based interventions for targeting suicidal thinking in students are lacking.

This project will evaluate the feasibility of a novel psychological intervention, called the Broad Minded Affective Coping (BMAC) intervention. The BMAC aims to increase peoples' access to positive thoughts and emotions to help them to break out of cycles of negative mood and suicidal thinking. It is targeted, protocolised, and deliverable by a range of professional groups. Our existing co-development work with young people has suggested that it is acceptable and helpful to University students. This randomised controlled feasibility trial of the BMAC intervention for suicidal thinking in university students. Participants will be randomised to either a risk assessment and signposting plus the BMAC (n = 33), or risk assessment and signposting alone (n = 33). The study will assess outcomes at baseline and after eight weeks, 16 weeks, and 24 weeks. The study will explore the safety, feasibility and acceptability of delivering the intervention and trial procedures. Embedded qualitative interviews with staff and participants, and field notes, will help us to understand the potential factors affecting acceptability and delivery of the BMAC intervention and conduct of the trial, and the proposed underlying mechanisms of change. The project will be a crucial step in evaluating the BMAC for suicidal students, paving the way for a larger trial of clinical effectiveness.

02

Conditions studied

  • Suicide, Attempted
  • Suicidal Ideation
03

In context

Suicide, Attempted

281 studies on the registry are indexed under Suicide, Attempted; 90 are open to participants now.

This study's enrollment of 65 is below the median of 129 across 224 interventional studies indexed under Suicide, Attempted.

Browse Suicide, Attempted studies →

Lead sponsor

Greater Manchester Mental Health NHS Foundation Trust is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years.
  • Accessing full or part time education through a Higher Education Institution (HEI).
  • Suicidal ideation and/or behaviours in the past three months

Exclusion criteria

Exclusion Criteria:

  • Active/historical full threshold first episode psychosis or bipolar disorder
  • Known moderate to severe learning disability (IQ:\<70).
  • Organic cerebral disease/injury affecting receptive and expressive language comprehension.
  • Non-English speaking to the degree that the participant is unable to answer questions and give written .
  • Imminent and immediate risk to self or others, operationalised as the presence of active intent or planning to harm oneself or others in the near future (e.g. next month).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Broad-Minded Affective Coping Intervention + Risk assessment and signposting

    Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. They will then be offered six sessions of the Broad-Minded Affective Coping (BMAC) Intervention. Sessions will take place weekly where possible and the intervention window will be eight weeks. A booster session will be offered in the 8 weeks following the end of therapy.

    Other: Broad-Minded Affective Coping Intervention · Other: Risk Assessment and Signposting

  • Other
    Risk assessment and signposting + Treatment As Usual

    Participants will first receive one to two 50 minute sessions focused on risk assessment and management, including signposting to further support. In addition they will be able to access usual care from their University counselling service or other health services.

    Other: Risk Assessment and Signposting

Interventions

  • OtherBroad-Minded Affective Coping Intervention

    The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.

  • OtherRisk Assessment and Signposting

    A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.

06

What researchers measure

Primary outcomes

  1. Recruitment Rates

    Ability to randomise 66 participants in an 11-month recruitment window. Traffic light targets for the percentage of the target sample recruited is as follows: Green: ≥80%. Amber 60-\<80%. Red \<60%.

    Time frame: 2 years

  2. Adherence to treatment

    Percentage of participants receiving the minimum dose of BMAC therapy (≥2 sessions) within eight-week treatment window. Traffic light targets for the percentage of the target sample receiving the minimum dose is as follows: Green: ≥80%. Amber: 60-\<80%. Red: \<60%.

    Time frame: 24 weeks

  3. Suitability of proposed primary outcome

    Informed by qualitative workstream plus percentage of participants completing the Beck Scale for Suicidal ideation y(BSS) at all timepoints. Targets for the proportion of participants completing the BSS is as follows: Green: ≥80%. Amber: 60-\<80%. Red: \<60%.

    Time frame: Through study completion, an average of 24 weeks

  4. Occurrence of Adverse Reactions

    Monitoring and review of research related serious adverse events (SAEs). The Trial Steering Committee (TSC) will oversee SAEs across treatment arms.

    Time frame: Through study completion, an average of 24 weeks

Secondary outcomes

  1. Beck Scale of Suicidal Ideation (BSS)

    This is a 21-item questionnaire measuring suicidal thinking over the past week. Items are scored on a scale from 0 to 2, with total scores ranging from 0 to 38, higher scores indicating greater suicidal ideation.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

  2. Beck Hopelessness Scale (BHS)

    This is a 20-item questionnaire measuring feelings of hopelessness over the past week. Items are scored on a scale from 0 to 1 (true or false), with total scores ranging from 0 to 20, higher scores indicating greater hopelessness.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

  3. Defeat and Entrapment Scale short-form (DES - short)

    This is an 8-item questionnaire measuring feelings of defeat and entrapment. Items are scored on a scale from 0 to 4, with total scores ranging from 0 to 32, higher scores indicating greater perceived defeat and entrapment.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

  4. Generalised Anxiety Disorder Assessment (GAD-7)

    This is a 7-item questionnaire measuring anxiety symptoms over the preceding two weeks. Items are scored on a scale from 0 to 3, with total scores ranging from 0 to 21, higher scores indicating greater anxiety.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

  5. Positive and Negative Affect Schedule (PANAS)

    This is a 20-item questionnaire measuring positive and negative affective states. Items are scored on a scale from 0 to 5, with total scores ranging from 0 to 50 for the negative affect and positive affect subscales, where higher scores indicating experience of greater positive and negative affect, respectively.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

  6. Perceived Control of Internal States Scale (PCISS)

    This is an 18-item questionnaire measuring perceived control of internal states (e.g. emotions and cognitions). Items are scored on a scale from 1 to 5, with total scores ranging from 18 to 90, where higher scores indicating greater perceived control.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

  7. Patient Health Questionnaire (PHQ9)

    This is a 9-item questionnaire measuring depressive symptoms over the preceding two weeks. Items are scored on a scale from 0 to 3, with total scores ranging from 0 to 27, where higher scores indicating greater depression.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

  8. Perceived Stress Scale (PSS)

    This is a 10-item questionnaire measuring stress over the preceding month. Items are scored on a scale from 0 to 4, with total scores ranging from 0 to 40, where higher scores indicating greater stress.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

  9. The Self-Injurious Thoughts and Behaviours Interview (SITBI) + Linehan Suicide Attempt-Self-Injury Interview (SASII)

    The SITBI is a structured interview designed to assess self-injurious and suicidal thoughts and behaviours. The sections relating to suicide attempt and non-suicidal self-injury will be used. In these sections the frequency of suicidal and self-injurious behaviour over the preceding year, month, and week is assessed. These data on occurrence of suicidal and self-injurious behaviour will be used as a secondary outcome in the trial. Items adapted from the SASII regarding the frequency of self-harm occurring over one's life and since the last assessment, will also be used to supplement the SASII in assessing suicidal and self-injurious behaviour. Frequency of suicidal or self-harm behaviour since the previous assessment point will be recorded at each follow-up assessment using these measures.

    Time frame: Baseline, 8-weeks, 16-weeks, 24-weeks

07

Study locations

1 site
  • Greater Manchester Mental Health NHS Trust
    Manchester, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Oct 2023, 20 months.

Of 145 non-industry interventional studies with no phase under Suicide, Attempted, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 56. This study's 20 months is below that.

Counting every sponsor, half of 147 studies reached it within 37 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2022
First posted
Mar 25, 2022
StartActual
Feb 21, 2022
Primary completionActual
Oct 24, 2023
CompletionActual
Oct 24, 2023
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05296538
Lead sponsor
Greater Manchester Mental Health NHS Foundation Trust
Responsible party
Peter Taylor (Senior Clinical Lecturer, Greater Manchester Mental Health NHS Foundation Trust) — Principal investigator
First posted
Mar 25, 2022
Start date
Feb 21, 2022
Primary completion
Oct 24, 2023
Completion
Oct 24, 2023
Last update
Mar 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion